相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
C. David Mazer et al.
CIRCULATION (2020)
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial
Erik J. M. van Bommel et al.
KIDNEY INTERNATIONAL (2020)
Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)
Kevin Damman et al.
EUROPEAN JOURNAL OF HEART FAILURE (2020)
Empagliflozin in Heart Failure Diuretic and Cardiorenal Effects
Matthew Griffin et al.
CIRCULATION (2020)
Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment
Eva M. Boorsma et al.
NATURE REVIEWS CARDIOLOGY (2020)
Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial
David Z I Cherney et al.
Lancet Diabetes & Endocrinology (2020)
Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial
Jesper Jensen et al.
AMERICAN HEART JOURNAL (2020)
Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure The RECEDE-CHF Trial
Natalie A. Mordi et al.
CIRCULATION (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection Fraction
Massar Omar et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Uric acid and the cardio-renal effects of SGLT2 inhibitors
Clifford J. Bailey
DIABETES OBESITY & METABOLISM (2019)
Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF)
Jesper Jensen et al.
TRIALS (2019)
Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes
Claire C. J. Dekkers et al.
DIABETES OBESITY & METABOLISM (2019)
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial
Ofri Mosenzon et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Thomas A. Zelniker et al.
LANCET (2019)
Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials
Yumo Zhao et al.
DIABETES OBESITY & METABOLISM (2018)
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis
Karen M. Hallow et al.
DIABETES OBESITY & METABOLISM (2018)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Prognostic Value of Estimated Plasma Volume in Heart Failure
Kevin Duarte et al.
JACC-HEART FAILURE (2015)
Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus
Yuliya Lytvyn et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2015)
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
David Z. I. Cherney et al.
CIRCULATION (2014)
Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus
S. Sha et al.
DIABETES OBESITY & METABOLISM (2014)
Worsening renal function during renin-angiotensin-aldosterone system inhibitor initiation and long-term outcomes in patients with left ventricular systolic dysfunction
Hannah Clark et al.
EUROPEAN JOURNAL OF HEART FAILURE (2014)
Uric acid and risk of heart failure: a systematic review and meta-analysis
He Huang et al.
EUROPEAN JOURNAL OF HEART FAILURE (2014)
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
H. J. Lambers Heerspink et al.
DIABETES OBESITY & METABOLISM (2013)
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
J-F Yale et al.
DIABETES OBESITY & METABOLISM (2013)
Albuminuria in chronic heart failure: prevalence and prognostic importance
Colette E. Jackson et al.
LANCET (2009)
Blood Urea Nitrogen and Serum Creatinine Not Married in Heart Failure
Roben W. Schrier
CIRCULATION-HEART FAILURE (2008)
分享论文
